Monthly Prescribing Reference

Additional injection site approved for Risperdal Consta

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
Forbes

Risperdal Lawsuit Update

For nearly a decade, Toni Matthews-El has published business topics ranging from cloud communication software to best steps for establishing your own LLC. In addition to Forbes Advisor, she's ...
Business Wire

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell ...
FiercePharma

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
FierceBiotech

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Release: FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia

TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...
Monthly Prescribing Reference

Application for Long-Acting Schizophrenia Treatment Accepted for Review

Syringe and Vials Patients treated with the investigational subcutaneous risperidone injection experienced a statistically significant delay in the time to relapse. The Food and Drug Administration ...
Nasdaq

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive ...
EurekAlert!

New study demonstrates key benefits of RISPERDAL(R) CONSTA(R) in young adults with schizophrenia

10 February 2004 – Davos – Young adults, aged between 18 and 30, diagnosed with schizophrenia and considered symptomatically stable on their antipsychotic treatment, experience significant ...